{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T17:41:46Z","timestamp":1762105306709,"version":"build-2065373602"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T00:00:00Z","timestamp":1720483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T00:00:00Z","timestamp":1720483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Appl Genetics"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s13353-024-00881-0","type":"journal-article","created":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T01:01:51Z","timestamp":1720486911000},"page":"347-362","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Identifying key genes and functionally enriched pathways in acute myeloid leukemia by weighted gene co-expression network analysis"],"prefix":"10.1007","volume":"66","author":[{"given":"Jimo","family":"Jian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenglu","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyuan","family":"Hao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,9]]},"reference":[{"issue":"12","key":"881_CR1","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1182\/blood-2009-11-250878","volume":"116","author":"S Abbas","year":"2010","unstructured":"Abbas S et al (2010) Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. Blood 116(12):2122\u20132126","journal-title":"Blood"},{"key":"881_CR2","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nature12477","volume":"500","author":"LB Alexandrov","year":"2013","unstructured":"Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SAJR, Behjati S, Biankin AV et al (2013) Signatures of mutational processes in human cancer. Nature 500:415\u2013421","journal-title":"Nature"},{"key":"881_CR3","doi-asserted-by":"publisher","first-page":"89566","DOI":"10.18632\/oncotarget.20023","volume":"8","author":"RA Alharbi","year":"2017","unstructured":"Alharbi RA, Pandha HS, Simpson GR, Pettengell R, Poterlowicz K, Thompson A et al (2017) Inhibition of HOX\/PBX dimer formation leads to necroptosis in acute myeloid leukemia cells. Oncotarget 8:89566\u201389579","journal-title":"Oncotarget"},{"key":"881_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/gb-2010-11-10-r106","volume":"11","author":"S Anders","year":"2010","unstructured":"Anders S, Huber W (2010) Differential expression analysis for sequence count data. Genome Biol 11:1\u201312","journal-title":"Genome Biol"},{"key":"881_CR5","doi-asserted-by":"publisher","first-page":"2832","DOI":"10.1128\/MCB.26.7.2832-2844.2006","volume":"26","author":"HK Arnold","year":"2006","unstructured":"Arnold HK, Sears RC (2006) Protein phosphatase 2A regulatory subunit B56alpha associates with c-Myc and negatively regulates c-Myc accumulation. Mol Cell Biol 26:2832\u20132844","journal-title":"Mol Cell Biol"},{"issue":"19","key":"881_CR6","doi-asserted-by":"publisher","first-page":"4707","DOI":"10.7150\/jca.31234","volume":"10","author":"CT Chen","year":"2019","unstructured":"Chen CT, Wang PP, Mo WJ, Zhang YP, Zhou W, Deng TF et al (2019) Expression profile analysis of prognostic long non-coding RNA in adult acute myeloid leukemia by weighted gene co-expression network analysis (WGCNA). J Cancer 10(19):4707\u20134718","journal-title":"J Cancer"},{"key":"881_CR7","first-page":"1","volume":"10","author":"J Cicenas","year":"2018","unstructured":"Cicenas J, Zalyte E, Bairoch A, Gaudet P (2018) Kinases and cancer. Cancers 10:1\u20137","journal-title":"Kinases and cancer. Cancers"},{"key":"881_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/nar\/gkv1507","volume":"44","author":"A Colaprico","year":"2016","unstructured":"Colaprico A, Silva TC, Olsen C, Garofano L, Cava C, Garolini D et al (2016) TCGAbiolinks: an R\/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res 44:1\u201311","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"881_CR9","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/j.1365-2141.2011.08737.x","volume":"154","author":"A De Weer","year":"2011","unstructured":"De Weer A, Van der Meulen J, Rondou P, Taghon T, Konrad TA, De Preter K et al (2011) EVI1-mediated down regulation of MIR449A is essential for the survival of EVI1 positive leukaemic cells. Br J Haematol 154(3):337\u2013348","journal-title":"Br J Haematol"},{"issue":"25","key":"881_CR10","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","volume":"378","author":"CD DiNardo","year":"2018","unstructured":"DiNardo CD, Stein EM, de Botton S, Roboz GJ, Altman JK, Mims AS et al (2018) Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. New Engl J Med 378(25):2386\u20132398","journal-title":"New Engl J Med"},{"key":"881_CR11","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H D\u00f6hner","year":"2015","unstructured":"D\u00f6hner H, Weisdorf DJ, Bloomfield CD (2015) Acute myeloid leukemia. N Engl J Med 373:1136\u20131152","journal-title":"N Engl J Med"},{"issue":"4","key":"881_CR12","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, B\u00fcchner T et al (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129(4):424\u2013447","journal-title":"Blood"},{"key":"881_CR13","doi-asserted-by":"crossref","unstructured":"De Weer AN, Mestdagh P, Preter KD, Meulen JVD, SpelemanF (2009) Downregulation of MiR-449a is essential for the survival of EVI1 positive leukemic cells through modulation of NOTCH1 and BCL2. Blood 114(22):361","DOI":"10.1182\/blood.V114.22.361.361"},{"key":"881_CR14","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1097\/CAD.0000000000000358","volume":"27","author":"AK Enjeti","year":"2016","unstructured":"Enjeti AK, Angel D\u2019C, Melville K, Verrills NM, Rowlings P, (2016) A systematic evaluation of the safety and toxicity of fingolimod for its potential use in the treatment of acute myeloid leukaemia. Anti-Cancer Drugs 27:560\u2013568","journal-title":"Anti-Cancer Drugs"},{"key":"881_CR15","doi-asserted-by":"crossref","unstructured":"Feng Y, Feng F, Pan S, Zhang J, Li W (2023) Fingolimod ameliorates chronic experimental autoimmune neuritis by modulating inflammatory cytokines and Akt\/mTOR\/NF-\u03baB signaling, 13. Brain Behav (4):e2965","DOI":"10.1002\/brb3.2965"},{"key":"881_CR16","doi-asserted-by":"publisher","first-page":"1077381","DOI":"10.3389\/fnmol.2022.1077381","volume":"15","author":"V Ferret-Sena","year":"2022","unstructured":"Ferret-Sena V, Capela C, Macedo A, Salgado AV, Derudas B, Staels B et al (2022) Fingolimod treatment modulates PPAR\u03b3 and CD36 gene expression in women with multiple sclerosis. Front Mol Neurosci 15:1077381","journal-title":"Front Mol Neurosci"},{"issue":"3","key":"881_CR17","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1182\/blood-2004-05-1846","volume":"105","author":"W Fiedler","year":"2005","unstructured":"Fiedler W, Serve H, D\u00f6hner H, Schwittay M, Ottmann OG, O\u2019Farrell AM, Bello CL et al (2005) A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 105(3):986\u2013993","journal-title":"Blood"},{"key":"881_CR18","doi-asserted-by":"crossref","unstructured":"Fiedler W, Kayser S, Kebenko M, Krauter J, Schlenk RF (2012) Sunitinib and intensive chemotherapy in patients with acute myeloid leukemia and activating FLT3 mutations: results of the AMLSG 10-07 study (ClinicalTrials.gov No. NCT00783653). Blood 120(21):1483","DOI":"10.1182\/blood.V120.21.1483.1483"},{"issue":"4","key":"881_CR19","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.hoc.2017.03.002","volume":"31","author":"JS Garcia","year":"2017","unstructured":"Garcia JS, Stone R (2017) The development of FLT3 inhibitors in acute myeloid leukemia. Hematol Clin North Am 31(4):663\u2013680","journal-title":"Hematol Clin North Am"},{"key":"881_CR20","doi-asserted-by":"publisher","first-page":"3673","DOI":"10.1093\/bioinformatics\/btv408","volume":"31","author":"JS Gehring","year":"2015","unstructured":"Gehring JS, Fischer B, Lawrence M, Huber W (2015) SomaticSignatures: inferring mutational signatures from single-nucleotide variants. Bioinformatics 31:3673\u20133675","journal-title":"Bioinformatics"},{"issue":"6","key":"881_CR21","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.hoc.2011.09.018","volume":"25","author":"D Grimwade","year":"2011","unstructured":"Grimwade D, Mrozek K (2011) Diagnostic and prognostic value of cytogenetics in acute myeloid leukemia. Hematol-Oncol Clin North Am 25(6):1135\u20131161","journal-title":"Hematol-Oncol Clin North Am"},{"key":"881_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2019\/7239206","volume":"2019","author":"L Handschuh","year":"2019","unstructured":"Handschuh L (2019) Not only mutations matter: molecular picture of acute myeloid leukemia emerging from transcriptome studies. J Oncol 2019:1\u201336","journal-title":"J Oncol"},{"key":"881_CR23","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1002\/gcc.22756","volume":"58","author":"L Hartmann","year":"2019","unstructured":"Hartmann L, Metzeler KH (2019) Clonal hematopoiesis and preleukemia\u2014genetics, biology, and clinical implications. Genes Chromosomes Canc 58:828\u2013838","journal-title":"Genes Chromosomes Canc"},{"issue":"2","key":"881_CR24","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1021\/jm201198w","volume":"55","author":"DK Heidary","year":"2012","unstructured":"Heidary DK, Huang G, Boucher D, Ma J, Forster C, Grey R et al (2012) VX-322: a novel dual receptor tyrosine kinase inhibitor for the treatment of acute myelogenous leukemia. J Med Chem 55(2):725\u2013734","journal-title":"J Med Chem"},{"key":"881_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-019-5822-y","volume":"19","author":"H Huang","year":"2019","unstructured":"Huang H, Chen F, Chou W, Hou H, Ko B, Lin C et al (2019) Long non-coding RNA HOXB-AS3 promotes myeloid cell proliferation and its higher expression is an adverse prognostic marker in patients with acute myeloid leukemia and myelodysplastic syndrome. BMC Cancer 19:1\u201314","journal-title":"BMC Cancer"},{"issue":"1","key":"881_CR26","doi-asserted-by":"publisher","first-page":"15658","DOI":"10.1038\/s41598-023-42700-2","volume":"13","author":"W Huang","year":"2023","unstructured":"Huang W, Zheng S, Wang Q, Zhao N, Long Z (2023) Identification and validation of a prognostic risk-scoring model based on the level of TIM-3 expression in acute myeloid leukemia. Sci Rep 13(1):15658","journal-title":"Sci Rep"},{"issue":"9","key":"881_CR27","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1038\/leu.2014.124","volume":"28","author":"AP Im","year":"2014","unstructured":"Im AP, Sehgal AR, Carroll MP, Smith BD, Tefferi A, Johnson DE et al (2014) DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies. Leukemia 28(9):1774\u20131783","journal-title":"Leukemia"},{"key":"881_CR28","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.gde.2004.12.004","volume":"15","author":"V Janssens","year":"2005","unstructured":"Janssens V, Goris J, Hoof CV (2005) PP2A: the expected tumorsuppressor. Curr Opin Genet Dev 15:34\u201341","journal-title":"Curr Opin Genet Dev"},{"key":"881_CR29","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1200\/EDBK_199519","volume":"38","author":"A Kuykendall","year":"2018","unstructured":"Kuykendall A, Duployez N, Boissel N, Lancet JE, Welch JS (2018) Acute myeloid leukemia: the good, the bad, and the ugly. Am Soc Clin Oncol Educ Book 38:555\u2013573","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"881_CR30","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1182\/asheducation-2013.1.220","volume":"2013","author":"M Levis","year":"2013","unstructured":"Levis M (2013) FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013? Hematology Am Soc Hematol Educ Program 2013:220\u2013226","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"22","key":"881_CR31","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","volume":"368","author":"TJ Ley","year":"2013","unstructured":"Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ, Robertson A et al (2013) Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 368(22):2059\u20132074","journal-title":"N Engl J Med"},{"issue":"8","key":"881_CR32","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.21037\/tcr-23-85","volume":"12","author":"X Li","year":"2023","unstructured":"Li X, Xu L (2023) Exploring prognostic markers for patients with acute myeloid leukemia based on cuproptosis related genes. Transl Cancer Res 12(8):2008\u20132022","journal-title":"Transl Cancer Res"},{"key":"881_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ncomms1681","volume":"3","author":"Z Li","year":"2012","unstructured":"Li Z, Huang H, Chen P, He M, Li Y, Arnovitz S et al (2012) miR-196b directly targets both HOXA9\/MEIS1 oncogenes and FAS tumour suppressor in MLL-rearranged leukaemia. Nat Commun 3:1\u201313","journal-title":"Nat Commun"},{"issue":"1","key":"881_CR34","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s40164-022-00335-5","volume":"11","author":"X Li","year":"2022","unstructured":"Li X, Qi J, Song X, Xu X, Pan T, Wang H et al (2022) DLC1 deficiency at diagnosis predicts poor prognosis in acute myeloid leukemia. Exp Hematol Oncol 11(1):74","journal-title":"Exp Hematol Oncol"},{"key":"881_CR35","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.bbrc.2015.10.071","volume":"467","author":"O Lindblad","year":"2015","unstructured":"Lindblad O, Chougule R, Moharram SA, Kabir NN, Sun J, Kazi JU et al (2015) The role of HOXB2 and HOXB3 in acute myeloid leukemia. Biochem Bioph Res Co 467:742\u2013747","journal-title":"Biochem Bioph Res Co"},{"issue":"4","key":"881_CR36","doi-asserted-by":"publisher","first-page":"913","DOI":"10.21037\/tcr-22-2484","volume":"12","author":"Y Liu","year":"2023","unstructured":"Liu Y, Cao Y, Yang X, Chen H, Yang H, Liu Y et al (2023) High expression of miR-107 and miR-17 predicts poor prognosis and guides treatment selection in acute myeloid leukemia. Transl Cancer Res 12(4):913\u2013927","journal-title":"Transl Cancer Res"},{"issue":"1","key":"881_CR37","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S0950-3536(96)80041-2","volume":"9","author":"B L\u00f6wenberg","year":"1996","unstructured":"L\u00f6wenberg B (1996) Treatment of the elderly patient with acute myeloid leukaemia. Bailli\u00e8res Clin Haematol 9(1):147\u2013159","journal-title":"Bailli\u00e8res Clin Haematol"},{"key":"881_CR38","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1101\/gr.239244.118","volume":"28","author":"A Mayakonda","year":"2018","unstructured":"Mayakonda A, Lin D, Assenov Y, Plass C, Koeffler HP (2018) Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res 28:1747\u20131756","journal-title":"Genome Res"},{"key":"881_CR39","doi-asserted-by":"publisher","first-page":"e229","DOI":"10.1016\/S1470-2045(12)70558-2","volume":"14","author":"D Perrotti","year":"2013","unstructured":"Perrotti D, Neviani P (2013) Protein phosphatase 2A: a target for anticancer therapy. Lancet Oncol 14:e229\u2013e238","journal-title":"Lancet Oncol"},{"issue":"11","key":"881_CR40","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1200\/JCO.2009.25.4888","volume":"28","author":"F Ravandi","year":"2010","unstructured":"Ravandi F, Cortes JE, Jones D, Faderl S, Garcia-Manero G, Konopleva MY, O\u2019Brien S, Estrov Z, Borthakur G, Thomas D, Pierce SR, Brandt M, Byrd A, Bekele BN, Pratz K, Luthra R, Levis M, Andreeff M, Kantarjian HM (2010) Phase I\/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol 28(11):1856\u20131862","journal-title":"J Clin Oncol"},{"key":"881_CR41","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/ng0506-500","volume":"38","author":"M Reich","year":"2006","unstructured":"Reich M, Liefeld T, Gould J, Lerner J, Tamayo P, Mesirov JP (2006) GenePattern 2.0. Nat Gent 38:500\u2013501","journal-title":"Nat Gent"},{"key":"881_CR42","doi-asserted-by":"publisher","first-page":"5438","DOI":"10.1158\/0008-5472.CAN-09-2544","volume":"70","author":"KG Roberts","year":"2010","unstructured":"Roberts KG, Smith AM, McDougall F, Carpenter H, Horan M, Neviani P et al (2010) Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers. Cancer Res 70:5438\u20135447","journal-title":"Cancer Res"},{"key":"881_CR43","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1002\/emmm.201201283","volume":"5","author":"SA Saddoughi","year":"2013","unstructured":"Saddoughi SA, Gencer S, Peterson YK, Ward KE, Mukhopadhyay A, Oaks J et al (2013) Sphingosine analogue drug FTY720 targets I2PP2A\/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis. MBO Mol Med 5:105\u2013121","journal-title":"MBO Mol Med"},{"issue":"3","key":"881_CR44","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1182\/blood-2007-11-121871","volume":"112","author":"MV Shah","year":"2008","unstructured":"Shah MV, Zhang R, Irby R, Kothapalli R, Liu X, Arrington T et al (2008) Molecular profiling of LGL leukemia reveals role of sphingolipid signaling in survival of cytotoxic lymphocytes. Blood 112(3):770\u2013781","journal-title":"Blood"},{"issue":"6","key":"881_CR45","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.exphem.2009.04.002","volume":"37","author":"J Shipley","year":"2009","unstructured":"Shipley J, Butera JN (2009) Acute myelogenous leukemia. Exp Hematol 37(6):649\u2013658","journal-title":"Exp Hematol"},{"key":"881_CR46","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68:7\u201330","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"881_CR47","doi-asserted-by":"publisher","first-page":"3669","DOI":"10.1182\/blood-2003-11-3775","volume":"103","author":"BD Smith","year":"2004","unstructured":"Smith BD, Levis M, Beran M, Giles F, Kantarjian H, Berg K et al (2004) Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 103(10):3669\u20133676","journal-title":"Blood"},{"issue":"6","key":"881_CR48","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","volume":"130","author":"EM Stein","year":"2017","unstructured":"Stein EM, DiNardo CD, Pollyea DA, Fathi AT, Roboz GJ, Altman JK et al (2017) Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood 130(6):722\u2013731","journal-title":"Blood"},{"issue":"12","key":"881_CR49","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1016\/j.leukres.2008.04.026","volume":"32","author":"AR Walker","year":"2008","unstructured":"Walker AR, Komrokji RS, Ifthikharuddin J, Messina P, Mulford D, Becker M et al (2008) Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed\/refractory AML. Leuk Res 32(12):1830\u20131836","journal-title":"Leuk Res"},{"key":"881_CR50","doi-asserted-by":"crossref","unstructured":"Wang X, Bajpai AK, Gu Q, Ashbrook DG, Starlard-Davenport A, Lu L (2023) Weighted gene co-expression network analysis identifies key hub genes and pathways in acute myeloid leukemia. Front Genet 14:1009462","DOI":"10.3389\/fgene.2023.1009462"},{"key":"881_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1177271919846454","volume":"14","author":"KK Wong","year":"2019","unstructured":"Wong KK, Lawrie CH, Green TM (2019) Oncogenic roles and inhibitors of DNMT1, DNMT3A, and DNMT3B in acute myeloid leukaemia. Biomarker Insights 14:1\u201312","journal-title":"Biomarker Insights"},{"issue":"6","key":"881_CR52","first-page":"4332","volume":"15","author":"JY Xie","year":"2023","unstructured":"Xie JY, Wang WJ, Wang N, Dong Q, Han H, Feng YP et al (2023) A novel immune-related gene signature correlated with serum IL33 expression in acute myeloid leukemia prognosis. Am J Transl Res 15(6):4332\u20134344","journal-title":"Am J Transl Res"},{"key":"881_CR53","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s12935-018-0621-0","volume":"18","author":"X Yin","year":"2018","unstructured":"Yin X, Huang S, Zhu R, Fan F, Sun C, Hu Y (2018) Identification of long non-coding RNA competing interactions and biological pathways associated with prognosis in pediatric and adolescent cytogenetically normal acute myeloid leukemia. Cancer Cell Int 18:122","journal-title":"Cancer Cell Int"},{"key":"881_CR54","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1586\/ern.10.98","volume":"10","author":"EM Yiu","year":"2010","unstructured":"Yiu EM, Banwell B (2010) Update on emerging therapies for multiple sclerosis. Expert Rev Neurother 10:1259\u20131262","journal-title":"Expert Rev Neurother"},{"key":"881_CR55","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu G, Wang L, Han Y, He Q (2012) clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS 16:284\u2013287","journal-title":"OMICS"},{"issue":"7","key":"881_CR56","doi-asserted-by":"publisher","first-page":"9055","DOI":"10.1002\/cam4.5644","volume":"12","author":"X Yu","year":"2023","unstructured":"Yu X, Chen C, Hu Y, Li K, Zhang Y, Chen Z et al (2023) High expression of LOC541471, GDAP1, SOD1, and STK25 is associated with poor overall survival of patients with acute myeloid leukemia. Cancer Med 12(7):9055\u20139067","journal-title":"Cancer Med"},{"key":"881_CR57","first-page":"1","volume":"4","author":"B Zhang","year":"2005","unstructured":"Zhang B, Horvath S (2005) A general framework for weighted gene co-expression network analysis. Stat Appl Genet Mol 4:1\u201345","journal-title":"Stat Appl Genet Mol"},{"issue":"1","key":"881_CR58","doi-asserted-by":"publisher","first-page":"6154","DOI":"10.1038\/s41467-021-26420-7","volume":"12","author":"L Zhang","year":"2021","unstructured":"Zhang L, Nguyen LXT, Chen YC, Wu D, Cook GJ, Hoang DH et al (2021) Targeting miR-126 in inv(16) acute myeloid leukemia inhibits leukemia development and leukemia stem cell maintenance. Nat Commun 12(1):6154","journal-title":"Nat Commun"},{"key":"881_CR59","doi-asserted-by":"publisher","first-page":"3376","DOI":"10.18632\/aging.101991","volume":"11","author":"J Zhou","year":"2009","unstructured":"Zhou J, Li X, Zhang T, Xu Z, Zhang Z, Gu Y et al (2009) MicroRNA-335\/ID4 dysregulation predicts clinical outcome and facilitates leukemogenesis by activating PI3K\/Akt signaling pathway in acute myeloid leukemia. Aging 11:3376\u20133391","journal-title":"Aging"}],"container-title":["Journal of Applied Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13353-024-00881-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13353-024-00881-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13353-024-00881-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T17:03:06Z","timestamp":1744736586000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13353-024-00881-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,9]]},"references-count":59,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["881"],"URL":"https:\/\/doi.org\/10.1007\/s13353-024-00881-0","relation":{},"ISSN":["1234-1983","2190-3883"],"issn-type":[{"type":"print","value":"1234-1983"},{"type":"electronic","value":"2190-3883"}],"subject":[],"published":{"date-parts":[[2024,7,9]]},"assertion":[{"value":"23 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Since this was a planning study without any delivery to any patient, there was no ethical approval required for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"That the article is original, has already been published in a preprint copy  (), and is not currently under consideration by another journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}